CNXUHealthcare · Biotechnology

CNXU Stock Forecast: Conexeu Sciences, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026

$2.83

−1.74% on the day

The 1 Wall Street analysts covering Conexeu Sciences, Inc. hold a median 12-month price target of $20 — +606.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$91.0M

Ticker Nerd rank

1/ 100

Median analyst target

$20

Analysts covering

Free cash flow−$1.8M

Quarterly, 4 quarters to 30 Apr 2026 · latest quarter's figure shown

Total return, dividends reinvested

−14.2%

−23.7%

From high

−83.2%

From low

0.0%

$17

Range since 21 May 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

CNXU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Conexeu Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026

1/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Issuance

Accruals

Growth

Value

Quality

Volatility

Momentum

Size (75): Smaller than most of the companies we track.

Momentum (0): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CNXU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNXU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 21 May 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $20Median $20High $20

The green dot is the last close — the median target sits +606.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
22 June 2026	HC Wainwright & Co.	Initiates	Buy	$20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CNXU appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

CNXU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

CNXU vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNXU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Conexeu Sciences, Inc. (CNXU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −14.9×
Price / sales: —
Price / book: 13.1×
EV / EBITDA: −6.2×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −332.9%
Return on assets: −170.7%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Conexeu Sciences, Inc. (CNXU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Conexeu Sciences, Inc. has a market value of $91.0M and an enterprise value of $81.7M.
Diluted earnings per share, trailing twelve months: $−0.23.
Free cash flow in the twelve months to 30 Apr 2026: −$4.1M, after $53K of capital spending.
Shares outstanding: 20.9M.
Trailing P/E: −14.9×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Conexeu Sciences, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

CNXU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CNXUConexeu Sciences, Inc.	$91.0M	1
EQEquillium, Inc.	$89.8M	37
NTHINeOnc Technologies Holdings, Inc.	$87.3M	20
ATRAAtara Biotherapeutics, Inc.	$86.9M	58
TNYATenaya Therapeutics, Inc.	$92.0M	35
TNXPTonix Pharmaceuticals Holding Corp.	$92.1M	32
RLYBRallybio Corp.	$84.4M	60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Conexeu Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNXU news & analysis

Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

GlobeNewsWire · 15 Oct 2026positive

Conexeu Sciences announced a $5 million private placement led by existing shareholders, management and directors, with the CEO and Chief Commercial Officer participating. The financing will support manufacturing scale-up, regulatory testing and preclinical work toward a planned FDA 510(k) submission in the first quarter of 2027.

Why it matters — CNXU watchers may follow the financing and its intended support for development and regulatory preparation.

Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

GlobeNewsWire · 6 Oct 2026positive

Conexeu Sciences provided an update on the regulatory and manufacturing program supporting its planned FDA 510(k) premarket notification for Ten Minute Tissue™, its lead wound care device candidate, and on broader commercialization preparations.

Why it matters — The update concerns regulatory and manufacturing work toward the planned FDA submission for CNXU’s lead device candidate.

Conexeu Sciences Sets September and October 2026 Conference Schedule

GlobeNewsWire · 1 Sept 2026neutral

Conexeu Sciences Inc. announced its participation in several investor and industry conferences scheduled for September and October 2026. The preclinical-stage biotechnology company is advancing an investigational tissue-restoration platform.

Why it matters — CNXU watchers may track the company's conference appearances for potential visibility and updates on its investigational tissue-restoration platform.

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

GlobeNewsWire · 18 Aug 2026positive

The article reports that peer-reviewed research is pointing to the extracellular matrix as central to regenerative work in medical aesthetics, and notes that more than a decade of research has gone into Conexeu Sciences' CXU™ Platform. A new category is described as forming in the field as research turns toward regeneration.

Why it matters — CNXU watchers would care because the piece highlights the depth of research behind Conexeu's CXU™ Platform and positions the company within an emerging regenerative category in medical aesthetics.

FAQ

Frequently asked questions about CNXU stock

What is the CNXU stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Conexeu Sciences, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNXU stock a buy right now?

Of the 1 analysts covering Conexeu Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Conexeu Sciences, Inc. 1 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNXU?

As at 28 Oct 2026, Conexeu Sciences, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (75 of 100).

Will CNXU stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +606.7% from the last close, and Ticker Nerd's factor model ranks Conexeu Sciences, Inc. 1 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNXU stock forecast for 2030?

No analyst covering Conexeu Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNXU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

What does Conexeu Sciences, Inc. do?

Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair.

What is the latest news on CNXU?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors". Conexeu Sciences announced a $5 million private placement led by existing shareholders, management and directors, with the CEO and Chief Commercial Officer participating. The financing will support manufacturing scale-up, regulatory testing and preclinical work toward a planned FDA 510(k) submission in the first quarter of 2027.

Company

About Conexeu Sciences, Inc.

Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair. Its core platform centers on a temperature-responsive extracellular matrix scaffold designed to support soft-tissue regeneration in applications such as wound care, dental repair, and medical aesthetics. The company’s products are intended to provide physicians with device-based tools for restoring tissue structure and function across clinical settings, including facial rejuvenation and body contouring uses. Conexeu Sciences operates in the regenerative medicine space, where collagen scaffold technologies are used to support healing, tissue in-growth, and improved patient outcomes. The company is based in Reno, Nevada, and is positioned as an early-stage developer of novel biomaterial solutions for both therapeutic and aesthetic markets.

CEO Mr. Miles D. Harrison · United States · https://www.conexeu.com